Krystal Biotech (NASDAQ:KRYS) Shares Gap Up – Still a Buy?

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) gapped up prior to trading on Wednesday . The stock had previously closed at $169.04, but opened at $176.59. Krystal Biotech shares last traded at $166.20, with a volume of 27,542 shares.

Analyst Ratings Changes

KRYS has been the topic of several research reports. Chardan Capital reissued a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a report on Thursday, December 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday. Finally, Stifel Nicolaus raised their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $206.67.

Krystal Biotech Stock Down 0.3 %

The firm’s 50-day moving average is $181.01 and its two-hundred day moving average is $185.37. The stock has a market cap of $4.85 billion, a P/E ratio of 95.50 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue was up 879.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.67) earnings per share. Analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Key Financial Inc acquired a new stake in Krystal Biotech during the 2nd quarter worth approximately $28,000. Blue Trust Inc. grew its stake in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the third quarter valued at $40,000. Values First Advisors Inc. bought a new stake in shares of Krystal Biotech during the third quarter valued at approximately $53,000. Finally, Quest Partners LLC bought a new stake in shares of Krystal Biotech during the second quarter worth about $71,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).